Cargando…
Evaluation of LY573144 (lasmiditan) in a preclinical model of medication overuse headache
BACKGROUND: Medication overuse is a significant issue that complicates the treatment of headache disorders. The most effective medications for the acute treatment of migraine all have the capacity to induce medication overuse headache (MOH). Novel acute migraine-specific treatments are being develop...
Autores principales: | Rau, Jill C, Navratilova, Edita, Oyarzo, Janice, Johnson, Kirk W, Aurora, Sheena K, Schwedt, Todd J, Dodick, David W, Porreca, Frank |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7412873/ https://www.ncbi.nlm.nih.gov/pubmed/32580575 http://dx.doi.org/10.1177/0333102420920006 |
Ejemplares similares
-
Ubrogepant does not induce latent sensitization in a preclinical model of medication overuse headache
por: Navratilova, Edita, et al.
Publicado: (2020) -
Preclinical assessment of onabotulinumtoxinA for the treatment of mild traumatic brain injury-related acute and persistent post-traumatic headache
por: Navratilova, Edita, et al.
Publicado: (2022) -
Safety and Risk of Medication Overuse Headache in Lasmiditan and Second-Generation Gepants: A Rapid Review
por: Lo Castro, Flavia, et al.
Publicado: (2021) -
Exploring the neurobiology of the premonitory phase of migraine preclinically – a role for hypothalamic kappa opioid receptors?
por: Kopruszinski, Caroline M., et al.
Publicado: (2022) -
Medication Overuse and Headache Burden: Results From the CaMEO Study
por: Schwedt, Todd J., et al.
Publicado: (2021)